BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...
BioAge Labs Inc.
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...
FierceBiotech4d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
Bioage Labs, Inc IPOs Tomorrow, Here's What You Need To Know
BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering ...
Nasdaq4d
BioAge Labs Rings the Opening Bell
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...
Ryan Reynolds's MNTN Explores Going Public, as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...